High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance)

Similar Items

• The mTORC1 Inhibitor Everolimus Combined with R-CHOP-21 for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Safety and Efficacy Results of a Phase I and Feasibility Trial NCCTG 1085 (Alliance)
  od: Johnston, Patrick B., i dr.
  Izdano: (2016)
• A Phase II Trial of The Oral Mtor Inhibitor Everolimus in Relapsed Hodgkin Lymphoma
  od: Johnston, Patrick B., i dr.
  Izdano: (2010)
• A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
  od: Witzig, T E, i dr.
  Izdano: (2011)
• The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma
  od: Witzig, Thomas E., i dr.
  Izdano: (2015)
• The Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) with Everolimus Results in Clinical Responses and Mobilization of CLL Cells into the Circulation
  od: Zent, Clive S., i dr.
  Izdano: (2010)